A Phase 3 interventional study of Indomethacin and Celecoxib in Arthritis, Gouty, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 81 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Arthritis, Gouty with a site in United States — 3 open to participants now, 4 under way, 1 of them phase 3. Arthritis, Gouty · United States.
Among the 15 studies in Arthritis, Gouty with a site in United States, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2008, is one of 5 in phase 3, and was the 1st registered.
47 studies on the registry are indexed under Arthritis, Gouty; 16 are open to participants now.
Browse Arthritis, Gouty studies →3 of the 15 studies in Arthritis, Gouty with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–90
Olatec Therapeutics, Inc. · Sites in United States, France, Israel and 2 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Arthritis, Gouty studies recruiting now, 8 (80%) set no upper age limit and 1 (10%) stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 6 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 402 is above the median of 140 across 35 interventional studies indexed under Arthritis, Gouty.
Median enrollment 225 across the 14 interventional studies, 843 across the 1 observational. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 9 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 1 study filed under Arthritis, Gouty — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Gouty with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT07116746Arthrosi TherapeuticsEvaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients | 2026-11 |
| NCT07346079Massachusetts General HospitalPurified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Arthritis, Gouty with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation of gouty arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Indomethacin
Drug: Celecoxib
Drug: Celecoxib
Drug: Celecoxib
indomethacin 50 mg three times a day (TID) for 8 days.
An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
Celecoxib 50 mg two times a day (BID) for 8 days
Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity
The Patient's Pain Intensity in the Index Joint for the prior 24 hours was assessed by completion of the following 5 point scale: My pain over the past 24 hours has been: None (0), Mild (1), Moderate (2), Severe (3), or Extreme (4).
Time frame: Baseline and Day 2
Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness
Tenderness was assessed on the basis of palpation or passive motion using a 4 point scale with the following ratings: the patient had no tenderness (0), the patient complained of pain (1), the patient complained of pain and winced (2) and the patient complained of pain, winced, and withdrew (3).
Time frame: Baseline, Day 5, Day 9, and Day 14/Early Termination
Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Swelling
Swelling was assessed using a 4 point scale with the following ratings: none (0), palpable (1), visible (2), and bulging beyond joint margins (3)
Time frame: Baseline, Days 5, 9 and 14/Early Termination
Number of Participants With Redness Present According to Physician's Assessment of the Index Joint on Day 5, Day 9, and Day 14/Early Termination
Redness was assessed by the physician as present or absent.
Time frame: Baseline, Day 5, Day 9 and Day 14/Early Termination
Number of Participants With Warmth Present According to Physician's Assessment of the Index Joint on Day 5, Day 9, and Day 14
Warmth was assessed by the physician as present or absent.
Time frame: Baseline, Day 5, Day 9 and Day 14
Change From Baseline in Patient's Assessment of Pain Intensity
The Patient's assessment of pain for the prior 24 hours was assessed by completion of the following 5 point scale: My pain over the past 24 hours has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4).
Time frame: Baseline, Day 2 to Day 13
Change From Baseline in Patient's Assessment of Pain Intensity on Day 1
The patient's assessment of pain was assessed by completion of the following 5 point scale: my pain at this time is none (0), mild (1), moderate, (2), severe (3), and extreme (4).
Time frame: Baseline, 2, 4, 8, 12 hours postdose Day 1, Day 2 (24 hours and 32 hours post first dose)
Change From Baseline in Time Weighted Average of Patient's Assessment of Pain Intensity Over 8, 12, and 24 Hours
Time weighted average over 8 (TWA-8), 12 (TWA-12) and 24 (TWA-24) hours post first dose of study medication on Day 1. Positive TWA values represent a reduction in pain intensity
Time frame: Baseline, 8, 12, and 24 hours post first dose
Number of Participants With ≥30% and ≥50% Reduction From Baseline to Day 2 in Patient's Assessment of Pain Intensity
The Patient's assessment of pain was assessed by completion of the following 5 point scale: My pain over the past 24 hours has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4).
Time frame: Baseline, Day 2
Participant's Assessment of Pain Intensity for the Average Pain Intensity at Baseline
The participant's assessment of pain was assessed by completion of the following 5 point scale: My pain has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4).
Time frame: Baseline
Percentage Change From Baseline in the Patient's Assessment of Pain Intensity for the Average Pain Intensity on Days 2-4, Days 2-8 and Days 2-13
The participant's assessment of pain was assessed by completion of the following 5 point scale: My change in pain has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4). Average change over days was calculated by taking the change from Baseline to the average Pain Intensity score over the days for each patient.
Time frame: Baseline to Day 13
Number of Participants With Withdrawal From Treatment Due to Lack of Efficacy
Withdrawal due to lack of efficacy was assessed from Days 1 to 8
Time frame: Day 1 to Day 8
Participants Global Evaluation of Study Medication Score
The participant rated the study medication that they received during the study by completing the following question: How would you rate the study medication you received for pain? 4=Excellent, 3=Good, 2=Fair, 1=Poor
Time frame: Day 9
Number of Participants With Pre-specified Gastrointestinal (GI) Adverse Events
The gastrointestinal tolerability was measured by incidence of moderate or severe GI adverse events (nausea, abdominal pain and dyspepsia)
Time frame: Baseline to Day 14/Early Termination
Number of Participants With Moderate or Severe Central Nervous System (CNS) Adverse Events
The pre-specfied CNS AEs were headache, nausea, dizziness, vertigo, vomiting and somnolence.
Time frame: Baseline to Day 14/Early Termination
| Milestone | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Started | 101 | 99 | 99 | 103 |
| Treated | 101 | 99 | 98 | 102 |
| Completed | 77 | 77 | 82 | 78 |
| Not completed | 24 | 22 | 17 | 25 |
| Withdrew: Adverse event | 5 | 3 | 1 | 9 |
| Withdrew: Lack of efficacy | 9 | 6 | 4 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 4 | 1 | 0 |
| Withdrew: Other | 9 | 9 | 9 | 11 |
| Withdrew: Randomized but not treated | 0 | 0 | 1 | 1 |
The Patient's Pain Intensity in the Index Joint for the prior 24 hours was assessed by completion of the following 5 point scale: My pain over the past 24 hours has been: None (0), Mild (1), Moderate (2), Severe (3), or Extreme (4).
| Scores on a scale | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Baseline | 3.03 ± 0.67 | 2.73 ± 0.62 | 2.84 ± 0.69 | 2.83 ± 0.76 |
| Change at Day 2 | -1.14 ± 1.10 | -1.23 ± 0.97 | -1.51 ± 1.11 | -1.62 ± 0.97 |
Tenderness was assessed on the basis of palpation or passive motion using a 4 point scale with the following ratings: the patient had no tenderness (0), the patient complained of pain (1), the patient complained of pain and winced (2) and the patient complained of pain, winced, and withdrew (3).
| Scores on a scale | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Baseline | 2.39 ± 0.72 | 2.15 ± 0.75 | 2.26 ± 0.65 | 2.13 ± 0.70 |
| Change at Day 5 | -1.44 ± 0.96 | -1.39 ± 0.89 | -1.58 ± 0.93 | -1.52 ± 0.86 |
| Change at Day 9 | -1.75 ± 0.98 | -1.64 ± 0.93 | -1.84 ± 0.92 | -1.65 ± 0.87 |
| Change at Day 14/Early Termination | -1.74 ± 1.09 | -1.66 ± 1.01 | -1.94 ± 0.88 | -1.64 ± 0.93 |
Swelling was assessed using a 4 point scale with the following ratings: none (0), palpable (1), visible (2), and bulging beyond joint margins (3)
| Scores on a scale | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Baseline | 2.16 ± 0.73 | 2.08 ± 0.65 | 2.09 ± 0.65 | 2.01 ± 0.75 |
| Change at Day 5 | -1.22 ± 1.09 | -1.21 ± 1.05 | -1.27 ± 0.97 | -1.20 ± 0.96 |
| Change at Day 9 | -1.47 ± 1.18 | -1.54 ± 1.00 | -1.62 ± 0.95 | -1.58 ± 0.94 |
| Change at Day 14/Early Termination | -1.55 ± 1.18 | -1.63 ± 0.98 | -1.78 ± 0.97 | -1.58 ± 0.94 |
Redness was assessed by the physician as present or absent.
| Participants | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Baseline | 84 | 88 | 79 | 85 |
| Day 5 | 27 | 29 | 26 | 23 |
| Day 9 | 12 | 15 | 13 | 11 |
| Day 14/Early termination | 15 | 15 | 7 | 13 |
Warmth was assessed by the physician as present or absent.
| Participants | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Baseline | 89 | 91 | 91 | 88 |
| Day 5 | 25 | 16 | 22 | 21 |
| Day 9 | 13 | 8 | 9 | 11 |
| DAY 14/E_TERM | 19 | 7 | 11 | 15 |
The Patient's assessment of pain for the prior 24 hours was assessed by completion of the following 5 point scale: My pain over the past 24 hours has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4).
| Scores on a scale | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Baseline | 3.03 ± 0.67 | 2.73 ± 0.62 | 2.84 ± 0.69 | 2.83 ± 0.76 |
| Change at Day 1 | -0.65 ± 0.87 | -0.85 ± 0.86 | -1.06 ± 1.08 | -1.10 ± 0.92 |
| Change at Day 2 | -1.14 ± 1.10 | -1.23 ± 0.97 | -1.51 ± 1.11 | -1.62 ± 0.97 |
| Change at Day 3 | -1.32 ± 1.15 | -1.42 ± 0.98 | -1.78 ± 1.09 | -1.84 ± 0.97 |
| Change at Day 4 | -1.52 ± 1.16 | -1.60 ± 0.98 | -1.96 ± 1.08 | -2.02 ± 1.00 |
| Change at Day 5 | -1.52 ± 1.16 | -1.67 ± 1.04 | -2.05 ± 1.10 | -2.04 ± 1.03 |
| Change at Day 6 | -1.68 ± 1.15 | -1.84 ± 1.05 | -2.12 ± 1.06 | -2.11 ± 1.01 |
| Change at Day 7 | -1.79 ± 1.23 | -1.90 ± 1.16 | -2.29 ± 1.05 | -2.15 ± 1.02 |
| Change at Day 8 | -1.88 ± 1.26 | -1.95 ± 1.12 | -2.30 ± 0.98 | -2.16 ± 1.04 |
| Change at Day 9 | -1.86 ± 1.27 | -1.96 ± 1.12 | -2.24 ± 1.04 | -2.19 ± 1.08 |
| Change at Day 10 | -1.90 ± 1.27 | -1.99 ± 1.13 | -2.23 ± 1.13 | -2.17 ± 1.01 |
| Change at Day 11 | -1.89 ± 1.31 | -1.94 ± 1.13 | -2.22 ± 1.15 | -2.15 ± 1.02 |
| Change at Day 12 | -1.93 ± 1.32 | -1.95 ± 1.18 | -2.27 ± 1.09 | -2.07 ± 1.07 |
| Change at Day 13/Early termination | -1.91 ± 1.34 | -1.95 ± 1.18 | -2.27 ± 1.08 | -1.98 ± 1.11 |
The patient's assessment of pain was assessed by completion of the following 5 point scale: my pain at this time is none (0), mild (1), moderate, (2), severe (3), and extreme (4).
| Scores on a scale | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Baseline | 3.03 ± 0.67 | 2.73 ± 0.62 | 2.84 ± 0.69 | 2.83 ± 0.76 |
| Change at Day 1, 2 HR | -0.32 ± 0.75 | -0.28 ± 0.67 | -0.45 ± 0.77 | -0.57 ± 0.88 |
| Change at Day 1, 4 HR | -0.53 ± 0.82 | -0.54 ± 0.69 | -0.70 ± 0.90 | -0.81 ± 0.92 |
| Change at Day 1, 8 HR | -0.64 ± 0.92 | -0.58 ± 0.73 | -0.87 ± 1.05 | -0.98 ± 0.94 |
| Change at Day 1, 12 HR | -0.73 ± 1.02 | -0.75 ± 0.79 | -1.02 ± 1.11 | -1.09 ± 0.96 |
| Change at Day 2, 0 HR | -0.93 ± 1.00 | -0.98 ± 0.88 | -1.15 ± 1.14 | -1.26 ± 0.93 |
| Change at Day 2, 8 HR | -1.08 ± 1.07 | -1.07 ± 0.96 | -1.31 ± 1.03 | -1.46 ± 0.93 |
Time weighted average over 8 (TWA-8), 12 (TWA-12) and 24 (TWA-24) hours post first dose of study medication on Day 1. Positive TWA values represent a reduction in pain intensity
| Scores on a scale | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Baseline | 3.03 ± 0.67 | 2.73 ± 0.62 | 2.84 ± 0.69 | 2.83 ± 0.76 |
| Change at 8 HR | 0.44 ± 0.66 | 0.42 ± 0.55 | 0.59 ± 0.74 | 0.69 ± 0.75 |
| Change at 12 HR | 0.52 ± 0.73 | 0.50 ± 0.58 | 0.71 ± 0.82 | 0.81 ± 0.79 |
| Change at 24 HR | 0.67 ± 0.81 | 0.68 ± 0.66 | 0.89 ± 0.93 | 0.99 ± 0.82 |
The Patient's assessment of pain was assessed by completion of the following 5 point scale: My pain over the past 24 hours has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4).
| Participants | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Reduction in Pain Intensity >= 30% | 58 | 69 | 75 | 82 |
| Reduction in Pain Intensity >= 50% | 43 | 57 | 63 | 71 |
The participant's assessment of pain was assessed by completion of the following 5 point scale: My pain has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4).
| Units on a scale | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Participant's Assessment of Pain Intensity for the Average Pain Intensity at Baseline | 3.03 ± 0.67 | 2.73 ± 0.62 | 2.84 ± 0.69 | 2.83 ± 0.76 |
The participant's assessment of pain was assessed by completion of the following 5 point scale: My change in pain has been: None (0), Mild (1), Moderate, (2), Severe (3), and Extreme (4). Average change over days was calculated by taking the change from Baseline to the average Pain Intensity score over the days for each patient.
| Percentage change | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Average change over days 2 - 4 | -44.13 ± 36.66 | -53.15 ± 34.17 | -60.11 ± 33.57 | 2.83 ± 0.76 |
| Average change over days 2 - 8 | -51.36 ± 35.57 | -61.83 ± 34.68 | -69.41 ± 30.86 | -70.05 ± 27.45 |
| Average change over days 2 - 13 | -56.11 ± 36.47 | -66.26 ± 35.55 | -73.59 ± 29.74 | -72.35 ± 27.39 |
Withdrawal due to lack of efficacy was assessed from Days 1 to 8
| Participants | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Day 1 | 2 | 1 | 0 | 0 |
| Any time during treatment | 10 | 8 | 4 | 3 |
| Any time during study | 11 | 9 | 5 | 4 |
The participant rated the study medication that they received during the study by completing the following question: How would you rate the study medication you received for pain? 4=Excellent, 3=Good, 2=Fair, 1=Poor
| Scores on a scale | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Participants Global Evaluation of Study Medication Score | 3.04 ± 0.87 | 3.11 ± 0.85 | 3.27 ± 0.69 | 3.33 ± 0.75 |
The gastrointestinal tolerability was measured by incidence of moderate or severe GI adverse events (nausea, abdominal pain and dyspepsia)
| Participants | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Number of Participants With Pre-specified Gastrointestinal (GI) Adverse Events | 1 | 0 | 2 | 3 |
The pre-specfied CNS AEs were headache, nausea, dizziness, vertigo, vomiting and somnolence.
| Participants | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Number of Participants With Moderate or Severe Central Nervous System (CNS) Adverse Events | 3 | 2 | 1 | 5 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Celecoxib 50 mg | — | 0/101 (0%) | 22/101 (21.8%) |
| Celecoxib 400/200 mg | — | 0/99 (0%) | 22/99 (22.2%) |
| Celecoxib 800/400 mg | — | 0/98 (0%) | 21/98 (21.4%) |
| Indomethacin 50 mg | — | 1/102 (1%) | 32/102 (31.4%) |
| Event | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Facial bones fractureInjury, poisoning and procedural complications | 0/101 | 0/99 | 0/98 | 1/102 |
| Event | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg |
|---|---|---|---|---|
| Gouty arthritisMusculoskeletal and connective tissue disorders | 4/101 | 7/99 | 3/98 | 6/102 |
| GoutMetabolism and nutrition disorders | 2/101 | 2/99 | 6/98 | 3/102 |
| DizzinessNervous system disorders | 2/101 | 1/99 | 2/98 | 6/102 |
| HeadacheNervous system disorders | 5/101 | 4/99 | 3/98 | 4/102 |
| Abdominal pain upperGastrointestinal disorders | 1/101 | 0/99 | 1/98 | 5/102 |
| DiarrhoeaGastrointestinal disorders | 3/101 | 2/99 | 2/98 | 5/102 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/101 | 4/99 | 3/98 | 2/102 |
| PyrexiaGeneral disorders | 4/101 | 1/99 | 0/98 | 0/102 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/101 | 1/99 | 3/98 | 1/102 |
| DyspepsiaGastrointestinal disorders | 2/101 | 0/99 | 2/98 | 3/102 |
| Age, Customized(Participants) | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg | Total |
|---|---|---|---|---|---|
| Between 18 and 65 years | 84 | 83 | 86 | 88 | 341 |
| >=65 years | 17 | 16 | 12 | 14 | 59 |
| Sex: Female, Male(Participants) | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg | Total |
|---|---|---|---|---|---|
| Female | 10 | 9 | 8 | 7 | 34 |
| Male | 91 | 90 | 90 | 95 | 366 |
| Race/Ethnicity, Customized(Participants) | Celecoxib 50 mg | Celecoxib 400/200 mg | Celecoxib 800/400 mg | Indomethacin 50 mg | Total |
|---|---|---|---|---|---|
| White | 53 | 64 | 54 | 55 | 226 |
| Black | 11 | 3 | 10 | 9 | 33 |
| Asian | 22 | 18 | 19 | 19 | 78 |
| Other | 15 | 14 | 15 | 19 | 63 |
The record gives a start of Feb 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →